secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001437749-21-026172
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica doses first patient in Phase 2/3 stroke trial; Q3 cash $48.1M after $30M raise
--------------------------------------------------------------------------------

- First patient dosed in pivotal ReMEDy2 trial of DM199 for acute ischemic stroke; ~350 patients planned.
- FDA granted Fast Track Designation for DM199 in AIS; protocol amendment adds stroke recurrence as primary endpoint.
- Completed $30M private placement in Sept 2021; cash, equivalents and marketable securities $48.1M at Sept 30.
- Q3 2021 R&D expenses $2.3M (vs $2.2M Q3 2020); net cash used in ops $9.4M for 9 months.
- Additional REDUX Phase 2 data in IgAN showed >30% reduction in albuminuria at ASN Kidney Week.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774921026172/0001437749-21-026172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774921026172/dmtp20211110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-026172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer